Dexcom Ventures will invest in glucose sensing technology and adjacent areas.
Month: February 2021
Warburtons chomps on Artful Baker
Break maker’s Batch Ventures will announce our second investment later this month.
Kraken Ventures awakes for crypto
Brandon Gath, previously head of corporate development at Kraken, has been made general partner of Kraken Ventures.
Fearless Fund shops for Costco
Fearless Fund is a US-based venture capital firm set up to invest in women of colour (WOC).
BBVA commits $150m to Propel
Propel was formed by Jay Reinemann and David Mort from spinning out BBVA’s corporate venturing unit.
SR One expands venture team
Chris Chai and Peter Van Vlasselaer, both former executives at SR One portfolio companies, have been hired by the GSK-backed VC firm as venture partners.
Corporate venturing deal net: 8-12 February 2021
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Forming a Spac – isn’t everyone?
It was catching up with a former corporate venturing leader this month as she described a healthy portfolio of activities covering public and private board roles and “forming a Spac – isn’t everyone?”
Alphabet helps provide $15m for Nothing
The stealthy consumer device startup took its total funding to $22m in just four months, with Alphabet unit GV leading its series A round.
Rover fetches SPAC for reverse merger
The Petco-backed pet services provider is set to be valued at about $1.6bn in a deal that will involve it listing on the Nasdaq Capital Market.
Nationwide expands venture capital allocation to $350m
The financial services and insurance group had initially earmarked about $100m for strategic investments in 2017 and has since backed 25 companies.
Hyperfine finds $90m in series D round
Alphabet’s GV unit and Huami both took part as the portable MRI device developer completed an oversubscribed series D round.
GrubMarket gets $90m in series D
Marubeni Ventures helped the online fresh food supplier push its overall funding past the $240m mark as it looks to expand further across the United States.
Binhui Biotech brings in series C funding
The Lepu-backed genetic cancer therapy developer has completed a $94.9m round co-led by CICC Capital, Share Capital, Vertex Ventures China and Qianhai FOF.